| Literature DB >> 34049936 |
Joeke Kootstra1, Tineke Kleinhout-Vliek2.
Abstract
INTRODUCTION: One way to prevent falsified medical products from entering the regulated pharmaceutical supply chain is to implement a pharmaceutical track-and-trace system (PTTS). Such systems in the most extensive versions generally mandate a scan at every point of contact with the medical product: from the point of entry to dispensation. There have been several attempts to implement such systems; for example, a 'full' PTTS in Turkey and the more pared-down version offered by the European Union's Falsified Medicines Directive and Delegated Act. This study aims to identify facilitators and barriers to implementing (elements of) a PTTS, with the Turkish system used as a benchmark.Entities:
Keywords: health policy; health systems; public health; review
Mesh:
Substances:
Year: 2021 PMID: 34049936 PMCID: PMC8166635 DOI: 10.1136/bmjgh-2020-003755
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Literature search process.
Political contextual factors identified affecting PTTSs; no data were retrieved for Ethiopia, Hong Kong, Pakistan, Taiwan and the UK
| Country | Government support | Legislation and regulation |
| Turkey | Governmental support and action, thanks to a political sense of urgency because of widespread reimbursement fraud. | Legislation and regulation were well defined. |
| Denmark | Legislation was becoming increasingly extensive and complex. | |
| Germany | Specific legislation and increased requirements of drug safety. Pharmaceutical companies that did not comply face fines and charges. | |
| India | Government started to realise the extent of the problem | … resulting in more extensive regulation. |
| Iran | A general lack of concern about the topic. | Little regulation was in place. |
| Poland | Requirements mainly regarding banning the marketing of SFMP. | |
| USA | The government was aware of the SFMP problem and recommended measures, | A framework for the guidance of PTTS efforts had been released, but states were developing their own laws. |
PTTS, pharmaceutical track-and-trace system; SFMP, substandard and falsified medical product.
Social contextual factors identified affecting PTTSs; no data were retrieved for Ethiopia, Pakistan, Taiwan and the UK
| Country | Supply chain actor support | Awareness, knowledge, and skill |
| Turkey | Stakeholders were sceptical at first but convinced along the way. | The problem of SFMP was widely recognised. |
| Denmark | The complexity of legislation made compliance highly demanding and set the bar too high for stakeholders. | |
| Germany | Stakeholders were aware of upcoming requirements, but personal concerns were the main drivers for adoption. | |
| Hong Kong | Fear of change was one of the critical barriers to implementation… | … but could be overcome with decent training. |
| India | There was no united effort from supply chain actors. | |
| Iran | Supply chain actors did not know about PTTS or the skills required. They were not even interested in using these technologies. | |
| Poland | Supply chain actors did not support the proposed changes. | There was little awareness nor consensus about the prevalence of SFMP and the upcoming European requirements. |
| USA | Supply chain actors wanted to implement PTTS as they were concerned about the consequences for their reputation and finances when they would become involved in an SFMP crisis. | There was widespread consensus about the benefits of PTTS implementations |
PTTS, pharmaceutical track-and-trace system; SFMP, substandard and falsified medical product.
Economic contextual factors identified affecting PTTSs; no data were retrieved for Denmark and India
| Country | Investments | Technical and digital capacities |
| Turkey | High costs imposed on stakeholders; however, not investing meant no sales, providing sufficient incentive to invest. | |
| Ethiopia | One of the lowest smartphone ownership rates globally hampered adoption. | |
| Germany | Minimal investments required. | Existing healthcare IT was fragmented, but this was well managed thanks to the adjustability of the system. |
| Hong Kong | Investments were required, but the effectiveness of the investment was unclear. Implementation was costly, time-consuming and difficult. | Current technical settings hampered the adoption of technologies. |
| Iran | Current ICT structures were insufficient for the application of PTTS technologies. | |
| Pakistan | The lack of digital inventory management was a key barrier. | |
| Poland | The proposed implementation required significant investments. | Pharmacies were not supported by electronic necessities. |
| Taiwan | High initial investments were the key barrier to implementation, especially since the eventual benefits were hard to envision. | |
| UK | Supply chain actors were expected to invest much time and workforce resources. | Hospitals did not have all technical prerequisites, and hospitals in rural areas might experience problems with their internet connection. |
| USA | Investments in terms of finances and staff necessary to implement PTTSs were extensive, and supply chain actors were hesitant of investing. | Most PTTSs were not interoperable with existing computer systems used by supply chain actors. |
ICT, information and communications technology; IT, information technology; PTTS, pharmaceutical track-and-trace system.